01
ABOUT THE EVENT
Virtual Symposium on Human Papillomavirus
HPV 2026
February 9, 2026
Format: Virtual
Organizer: IRC – Impact Research Communications
The HPV 2026 symposium convened leading researchers and
clinicians to explore the molecular, immunological, and
clinical dimensions of human papillomavirus (HPV) and its
associated cancers. The one-day program highlighted advances
in targeted therapies, immune modulation, diagnostics, and
genomic insights—underscoring the global commitment to
reducing HPV-related disease burden.
02
RESEARCH & DISCOVERIES
Scientific Highlights
Session I: Molecular Mechanisms & Oncoproteins
-
Dr. Jennifer Binning (USA)
presented engineered degraders of the HPV E6
oncoprotein, offering a novel therapeutic strategy
to dismantle viral oncogenesis.
-
Dr. Takuya Nakagawa (Japan)
discussed extrachromosomal DNA in HPV-associated
cancers, revealing its role in tumor evolution
and heterogeneity.
-
Dr. Simona Stolnicu (Romania)
emphasized HPV status as a critical factor in
classifying and prognosing cervical epithelial
malignancies.
-
Dr. Yotam Drier (Israel)
highlighted MYB overexpression and tumor
heterogeneity in HPV-related sinonasal and
adenoid cystic carcinomas.
Session II: Immunity, Immune Checkpoints & Genomic Disruption
-
Dr. Jian Zhu (USA)
examined immune dysregulation in HPV-associated
head and neck cancers, identifying pathways
of immune escape.
-
Dr. Khaled Sanber (USA)
demonstrated that intratumoral HPV16-reactive
CD8+ T cells correlate with response to immune
checkpoint blockade, pointing toward predictive
biomarkers.
-
Dr. Cristina Montagna (USA)
explored genome disruption in HPV-associated
lesions, linking structural changes to disease
progression.
-
Dr. Subhasis Biswas (USA)
connected HPV DNA replication, oncogene
transcription, and oncogenesis, offering a
systems-level view of viral persistence and
malignancy.
03
KEY FINDINGS
Key Takeaways
-
Targeted therapies:
Such as E6 degraders represent a promising frontier
in HPV oncology.
-
Genomic insights:
Into extrachromosomal DNA and structural disruption
deepen understanding of cancer progression.
-
Immune modulation:
And checkpoint blockade responses highlight the
importance of host-virus interactions.
-
Biomarkers and classification systems:
Are evolving to improve diagnosis, prognosis,
and treatment personalization.
04
INTERNATIONAL COLLABORATION
Global Participation
The symposium featured speakers from
USA, Japan, Romania, Israel, and France,
reflecting the international scope of HPV research
and collaboration.
05
CLOSING REMARKS
Conclusion
The HPV 2026 symposium showcased the convergence of
molecular biology, immunology, and clinical innovation
in tackling HPV-associated cancers. By advancing
targeted therapies, refining diagnostics, and harnessing
immune responses, the global research community continues
to move closer to reducing the burden of HPV-related disease.